Fasiglifam (TAK-875) acts as a novel, orally available, selective GPR40 agonist. TAK-875 (0.01-10 μM) produces a concentration-dependent increase in intracellular…
Fasiglifam (TAK-875) acts as a novel, orally available, selective GPR40 agonist. TAK-875 (0.01-10 μM) produces a concentration-dependent increase in intracellular…